Skip to main content

Active Immunisation for Chikungunya Virus Infection

1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Bharat Biotech
Bharat BiotechIndia - Hyderabad
1 program
1
BBV87 Chikungunya vaccinePhase 2/3Vaccine1 trial
Active Trials
NCT07555392Recruiting1,000Est. Aug 2027

Trial Timeline

Clinical trial activity over time

2026
2027
Bharat BiotechBBV87 Chikungunya vaccine

Clinical Trials (1)

Total enrollment: 1,000 patients across 1 trials

NCT07555392Bharat BiotechBBV87 Chikungunya vaccine

A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age.

Start: Apr 2026Est. completion: Aug 20271,000 patients
Phase 2/3Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 1,000 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.